Trial Profile

Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cixutumumab (Primary) ; Everolimus; Octreotide
Indications Adenocarcinoma; Gastrointestinal cancer; Glucagonoma; Insulinoma; Neuroendocrine carcinoma; Pancreatic cancer; Paraganglioma; Thyroid cancer
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

11 May 2016 Status changed from discontinued to completed.
29 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com